| Treat cancers by targeting survivin: just a dream or future reality? MS Coumar, FY Tsai, JR Kanwar, S Sarvagalla, CHA Cheung Cancer treatment reviews 39 (7), 802-811, 2013 | 188 | 2013 |
| The two sides of YY1 in cancer: a friend and a foe S Sarvagalla, SP Kolapalli, S Vallabhapurapu Frontiers in oncology 9, 1230, 2019 | 122 | 2019 |
| BIRC5/Survivin is a novel ATG12–ATG5 conjugate interactor and an autophagy-induced DNA damage suppressor in human cancer and mouse embryonic fibroblast cells TY Lin, HH Chan, SH Chen, S Sarvagalla, PS Chen, MS Coumar, ... Autophagy 16 (7), 1296-1313, 2020 | 105 | 2020 |
| Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013) CHA Cheung, S Sarvagalla, JYC Lee, YC Huang, MS Coumar Expert opinion on therapeutic patents 24 (9), 1021-1038, 2014 | 61 | 2014 |
| Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo … S Sarvagalla, VK Singh, YY Ke, HY Shiao, WH Lin, HP Hsieh, JTA Hsu, ... Journal of computer-aided molecular design 29, 89-100, 2015 | 42 | 2015 |
| Disruption of protein–protein interactions: hot spot detection, structure-based virtual screening and in vitro testing for the anti-cancer drug target–survivin S Sarvagalla, CHA Cheung, JY Tsai, HP Hsieh, MS Coumar Rsc Advances 6 (38), 31947-31959, 2016 | 39 | 2016 |
| Structural biology insight for the design of sub-type selective Aurora kinase inhibitors S Sarvagalla, M Selvaraj Coumar Current Cancer Drug Targets 15 (5), 375-393, 2015 | 30 | 2015 |
| Docking-based virtual screening using PyRx Tool: autophagy target Vps34 as a case study SK Kondapuram, S Sarvagalla, MS Coumar Molecular Docking for Computer-Aided Drug Design, 463-477, 2021 | 25 | 2021 |
| Targeting autophagy with small molecules for cancer therapy SK Kondapuram, S Sarvagalla, MS Coumar J Cancer Metastasis Treat, 2019 | 25 | 2019 |
| An overview of computational methods, tools, servers, and databases for drug repurposing S Sarvagalla, SB Syed, MS Coumar In silico drug design, 743-780, 2019 | 25 | 2019 |
| Identification of natural inhibitors of Bcr‐Abl for the treatment of chronic myeloid leukemia P Parcha, S Sarvagalla, B Madhuri, S Pajaniradje, V Baskaran, ... Chemical biology & drug design 90 (4), 596-608, 2017 | 21 | 2017 |
| Survivin-caspase protein-protein interaction: Experimental evidence and computational investigations to decipher the hotspot residues for drug targeting S Sarvagalla, TY Lin, SK Kondapuram, CHA Cheung, MS Coumar Journal of Molecular Structure 1229, 129619, 2021 | 11 | 2021 |
| Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia PK Parcha, S Sarvagalla, C Ashok, SJ Sudharshan, M Dyavaiah, ... Pharmacological Reports 73, 615-628, 2021 | 10 | 2021 |
| Functional inhibition of c-Myc using novel inhibitors identified through “hot spot” targeting A Singh, P Kumar, S Sarvagalla, T Bharadwaj, N Nayak, MS Coumar, ... Journal of Biological Chemistry 298 (5), 2022 | 8 | 2022 |
| Cloning, expression, and purification of the recombinant pro-apoptotic dominant-negative survivin T34A-C84A protein in Escherichia coli SL Tsai, YC Chang, S Sarvagalla, S Wang, MS Coumar, CHA Cheung Protein Expression and Purification 160, 73-83, 2019 | 8 | 2019 |
| Identification of a novel leukemic-specific splice variant of DNMT3B and its stability MSCSB Prachi Singh, Sarvagalla Sailu, Elango Palchamy Medical Oncology, 2017 | 4 | 2017 |
| Therapeutic polymeric nanoparticles and the methods of making and using thereof: A patent evaluation of WO2015036792 S Sarvagalla, HP Hsieh, MS Coumar Expert Opinion on Therapeutic Patents 26 (7), 751-755, 2016 | 3 | 2016 |
| Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase: In Silico Approach to Identify PPI Inhibitors S Sarvagalla, MS Coumar Pharmaceutical Sciences: Breakthroughs in Research and Practice, 1115-1143, 2017 | 2 | 2017 |
| Resources for docking-based virtual screening S Sarvagalla, SK Kondapuram, RV Devi, MS Coumar Molecular Docking for Computer-Aided Drug Design, 179-203, 2021 | 1 | 2021 |
| What can the anti-apoptotic molecule, BIRC5/Survivin, do in the autophagic world? CH Cheung, TY Lin, S Sarvagalla, MS Coumar, SM Cheng, E Leung CANCER SCIENCE 113, 2022 | | 2022 |
Mohane Coumar SAssistant Professor, Department of Bioinformatics, Pondicherry UniversityVerified email at bicpu.edu.in
